Kasim-Karakas SE, Almario RU, Gregory L, Wong R, Todd H, Lasley BL
In STEP-3 (N=611), semaglutide combined with intensive behavioral therapy produced a mean 16.0% body weight reduction at 68 weeks, with GI side effects reported in 82.8% of the semaglutide group versus 63.6% on placebo [7]
If you're going to freeze it, commit to it
KEY FEATURES BPC-157 lyophilised research-grade peptide 5mg per vial Independent HPLC-MS verified to 99.67% purity (CoA on public Lab Results portal) Single-batch fill, single-batch chromatogram no blending across lots Synthesised in accredited contract laboratories with full QA paper trail Crimp-sealed, tamper-evident research vial in unbranded outer packaging Dispatched from Australia on Auspost Express with insulated cold-pack option SPECIFICATIONS Product Name BPC-157 Category Healing Research Peptides Grade Research grade laboratory use only Quantity 5mg per vial Form Lyophilised powder cake Purity 99.67% verified by HPLC-MS Appearance White to off-white lyophilised solid Storage 28 C lyophilised
According to the Wegovy SmPC, while semaglutide delays gastric emptying, clinical pharmacology trials have shown no clinically relevant effect on the absorption of tested oral medicines